Fifteen Hub Genes Associated with Progression and Prognosis of Clear Cell Renal Cell Carcinoma Identified by Coexpression Analysis
Overview
Physiology
Authors
Affiliations
Renal cell carcinoma (RCC) is the most common type of renal tumor, and the clear cell renal cell carcinoma (ccRCC) is the most frequent subtype. In this study, our aim is to identify potential biomarkers that could effectively predict the prognosis and progression of ccRCC. First, we used The Cancer Genome Atlas (TCGA) RNA-sequencing (RNA-seq) data of ccRCC to identify 2370 differentially expressed genes (DEGs). Second, the DEGs were used to construct a coexpression network by weighted gene coexpression network analysis (WGCNA). Moreover, we identified the yellow module, which was strongly related to the histologic grade and pathological stage of ccRCC. Then, the functional annotation of the yellow module and single-samples gene-set enrichment analysis of DEGs were performed and mainly enriched in cell cycle. Subsequently, 18 candidate hub genes were screened through WGCNA and protein-protein interaction (PPI) network analysis. After verification of TCGA's ccRCC data set, Gene Expression Omnibus (GEO) data set (GSE73731) and tissue validation, we finally identified 15 hub genes that can actually predict the progression of ccRCC. In addition, by using survival analysis, we found that patients of ccRCC with high expression of each hub gene were more likely to have poor prognosis than those with low expression. The receiver operating characteristic curve showed that each hub gene could effectively distinguish between localized and advanced ccRCC. In summary, our study indicates that 15 hub genes have great predictive value for the prognosis and progression of ccRCC, and may contribute to the exploration of the pathogenesis of ccRCC.
Meng J, Jiang A, Lu X, Gu D, Ge Q, Bai S Imeta. 2024; 2(4):e147.
PMID: 38868222 PMC: 10989995. DOI: 10.1002/imt2.147.
Li T, Lin T, Zhu J, Zhou M, Fan S, Zhou H Front Oncol. 2023; 13:1222098.
PMID: 37736548 PMC: 10509477. DOI: 10.3389/fonc.2023.1222098.
Zhang Z, Tang Y, Li L, Yang W, Xu Y, Zhou J J Immunol Res. 2022; 2022:4946197.
PMID: 36313180 PMC: 9606837. DOI: 10.1155/2022/4946197.
Dong Y, Miao Q, Li D Comput Math Methods Med. 2022; 2022:6881600.
PMID: 35872941 PMC: 9303125. DOI: 10.1155/2022/6881600.
Wang Y, Nie H, Li H, Liao Z, Yang X, He X Front Med (Lausanne). 2022; 9:888093.
PMID: 35865173 PMC: 9295930. DOI: 10.3389/fmed.2022.888093.